8-K: CG Oncology Announces CFO Resignation and Interim Financial Leadership Appointment

CG Oncology, Inc. announced the resignation of its Chief Financial Officer, Corleen Roche, effective August 5, 2025, and the appointment of Robert Lapetina as interim principal financial and accounting officer.

Summary

• Corleen Roche, Chief Financial Officer of CG Oncology, Inc., delivered a 30-day notice of resignation from her position on July 7, 2025.
• Ms. Roche's resignation is effective August 5, 2025.
• Robert Lapetina was appointed as the interim principal financial and accounting officer of the Company, effective August 5, 2025.
• Mr. Lapetina has served as Vice President, Financial Planning & Analysis for CG Oncology since May 2024.
• He will serve in the interim role until a permanent replacement is found.
• Mr. Lapetina brings extensive experience, having previously served as Vice President, Finance and Corporate Controller and Principal Accounting Officer at Immunome, Inc., Assistant Vice President, North America Finance at The Chubb Corporation, Finance Director, Strategic Projects at Teleflex Inc., and Finance Portfolio Management Optimization Team Lead at Pfizer Inc.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the departure of a key executive (CFO), which introduces uncertainty. However, the appointment of an experienced interim leader mitigates some of the potential negative impact, preventing a lower score.

Positives

• The appointment of Robert Lapetina as interim principal financial and accounting officer ensures continuity, given his prior role as Vice President, Financial Planning & Analysis at CG Oncology since May 2024.
• Mr. Lapetina possesses extensive and relevant experience in finance and accounting roles across multiple reputable companies, including Immunome, The Chubb Corporation, Teleflex Inc., and Pfizer Inc., which should provide stability during the transition.

Negatives

• The departure of the Chief Financial Officer, Corleen Roche, creates a leadership vacancy in a critical executive role.
• The appointment of an interim officer indicates that a permanent replacement has not yet been identified, potentially leading to a period of uncertainty.

Risks

• Potential for disruption to financial operations and strategic planning due to the transition in financial leadership.
• Uncertainty regarding the timeline for identifying and appointing a permanent Chief Financial Officer.
• Possible impact on investor confidence due to the unexpected departure of a key executive.

Future Outlook

The Company will be seeking a permanent replacement for the principal financial and accounting officer role following the interim appointment of Robert Lapetina.

Industry Context

Executive leadership changes, particularly in key financial roles like CFO, are common occurrences in the dynamic biotechnology and pharmaceutical sectors. Companies often appoint interim leaders to ensure continuity while conducting a thorough search for a permanent replacement, especially in highly regulated industries where financial reporting is critical.

Management Changes

Stakeholder Impact

• Shareholders may experience increased uncertainty regarding the company's financial leadership and future strategic direction until a permanent CFO is appointed.
• Employees, particularly within the finance department, may face a period of adjustment and potential changes in reporting structures or priorities.

Next Steps

• The Company will conduct a search for a permanent principal financial and accounting officer.

Key Dates

Keywords

CG Oncology, CFO resignation, interim financial officer, executive change, corporate governance, biotechnology, pharmaceuticals, SEC filing, 8-K